Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes

Imeglimin is an investigational first‐in‐class novel oral agent for the treatment of type 2 diabetes (T2D). Several pivotal phase III trials have been completed with evidence of statistically significant glucose lowering and a generally favourable safety and tolerability profile, including the lack...

Descripción completa

Detalles Bibliográficos
Autores principales: Hallakou‐Bozec, Sophie, Vial, Guillaume, Kergoat, Micheline, Fouqueray, Pascale, Bolze, Sébastien, Borel, Anne‐Laure, Fontaine, Eric, Moller, David E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049051/
https://www.ncbi.nlm.nih.gov/pubmed/33269554
http://dx.doi.org/10.1111/dom.14277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049051/
https://www.ncbi.nlm.nih.gov/pubmed/33269554
http://dx.doi.org/10.1111/dom.14277

Ejemplares similares